Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/29147
Title: Alemtuzumab improves outcomes in RRMS patients who switched from SC IFNB-1a: 6-year follow-up of CARE-MS I Patients (TOPAZ Study)
Authors: Montalban, X.
Barone, D.
Broadley, S.
Dive, D.
Hupperts, R. M.
Lycke, J.
Massacesi, L.
Naismith, R. T.
Nakamura, K.
Pandey, K.
Schippling, S.
Vermersch, P.
Wiendl, H.
Chung, L.
Daizadeh, N.
Afsar, S.
VAN WIJMEERSCH, Bart 
Issue Date: 2019
Publisher: WILEY
Source: EUROPEAN JOURNAL OF NEUROLOGY, 26, p. 678-678
Notes: [Montalban, X.] Univ Toronto, St Michaels Hosp, Toronto, ON, Canada. [Barone, D.] Rowan Univ, Glassboro, NJ USA. [Broadley, S.] Griffith Univ, Sch Med, Gold Coast Campus, Southport, Qld, Australia. [Dive, D.] Univ Hosp Ctr Liege, Liege, Belgium. [Hupperts, R. M.] Maastricht Univ, Med Ctr, Orbis Med Ctr, Sittard, Netherlands. [Lycke, J.] Univ Gothenburg, Gothenburg, Sweden. [Massacesi, L.] Univ Florence, Florence, Italy. [Naismith, R. T.] Washington Univ, Sch Med, St Louis, MO USA. [Nakamura, K.] Cleveland Clin, Cleveland, OH 44106 USA. [Pandey, K.] Hackensack Univ Hosp, Multiple Sclerosis Care Ctr, Hackensack, NJ USA. [Schippling, S.] Univ Hosp Zurich, Neuroimmunol & Multiple Sclerosis Res, Zurich, Switzerland. [Schippling, S.] Univ Zurich, Zurich, Switzerland. [Vermersch, P.] Univ Lille, Lille, France. [Wiendl, H.] Univ Munster, Munster, Germany. [Chung, L.; Daizadeh, N.; Afsar, S.] Sanofi, Cambridge, MA USA. [Van Wijmeersch, B.] Hasselt Univ, Rehabil & MS Ctr Overpelt, BIOMED, Hasselt, Belgium.
Document URI: http://hdl.handle.net/1942/29147
ISSN: 1351-5101
e-ISSN: 1468-1331
ISI #: 000474481003051
Category: M
Type: Journal Contribution
Appears in Collections:Research publications

Show full item record

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.